HBIO - CONSENSUS CO - Harvard Bioscience

The laboratory equipment sector is characterized by fierce competition for government contracts and pressure from Eastern suppliers. Harvard Bioscience (HBIO) relies on consistent procurement from universities and pharmaceutical centers, which ensures a stable cash flow. The current figure is 7.51. Harvard Bioscience (HBIO) is scaling its product range by implementing automation for cell analysis. The historical price action is presented below and illustrates market sentiment toward the asset.

This indicator represents the weighted average fair value of the asset, calculated based on independent expert estimates to filter out market volatility. By analyzing the consensus target price forecast, an investor can see the aggregated potential of Harvard Bioscience (HBIO), which currently depends on the company's ability to scale sales of automated cell analysis systems amid stagnation in the academic segment.